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Abstract
Carotenoids are tetraterpenoid organic pigments synthesized by a variety of plants and 
microorganisms. Dietary carotenoids, taken by animals through food, play an essential 
role in cell differentiation, morphogenesis, vision, prevention of cancer, atherosclerosis, 
and age-related macular degeneration in humans due to their potential to suppress oxida-
tive stress. As reactive oxygen species and oxidative damage to biomolecules have been 
found to be involved in the causation and progression of chronic liver diseases (CLDs), 
including hepatocellular carcinoma (HCC), which is one of the major causes of morbidity 
and mortality worldwide. Therefore, dietary antioxidants, which inactivate reactive oxy-
gen species and obstruct oxidative damage, are considered as vital prophylactic strategic 
molecules. Data from various epidemiological studies and clinical trials strongly validate 
the observation that adequate carotenoid supplementation may significantly reduce the 
risk of several liver disorders. This chapter, thus, provides a comprehensive account of 
dietary carotenoids and includes the recent information with respect to their role in pre-
vention of liver diseases.
Keywords: β-carotene, lycopene, lutein, β-cryptoxanthin, oxidative stress, chronic liver 
diseases
1. Introduction
There are unambiguous evidences that regular consumption of vegetables and fruits decreases 
the prevalence of chronic liver disease (CLD) [1, 2]. One of the main reasons of the health 
organizations to increase the consumption of vegetables and fruits is that these are good 
sources of carotenoids and other biologically active phytochemicals. Carotenoids are natu-
rally occurring tetraterpenoids and represented by approximately 700 different structural 
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Figure 1. Functions of various dietary carotenoids against chronic liver diseases.
variants, but only 50 have been reported to play an important role in human diet [3]. They 
are synthesized by plants, fungi, algae, and bacteria [4]. They are classified into two groups, 
carotenes containing only carbon and hydrogen atoms and xanthophylls containing at least 
one oxygen atom [5]. These carotenoids are further paired into two classes, provitamin A 
carotenoids (β-carotene and β-cryptoxanthin) and non-provitamin A carotenoids (lycopene 
and lutein) [6]. In animals and human beings, carotenoids particularly β-carotene, lycopene, 
lutein, and β-cryptoxanthin play an important role in protection against photooxidative dam-
age by acting as singlet molecular oxygen and peroxy radical scavenger [7, 8]. There are 
increasing evidences that an alteration of the cellular redox state involving production of 
reactive oxygen species (ROS) plays a central role in different steps that initiate and regu-
late the progression of various liver diseases irrespective of the cause. Liver damage caused 
by reactive oxygen species is induced by alcohol, alteration of lipid, viruses, carbohydrate 
metabolism, and xenobiotics [9]. In this context, provitamin A activity of these carotenoids 
[10, 11] has received considerable interest by researchers and health professionals to prevent 
chronic liver diseases.
Chronic liver diseases (CLDs) are the major concern throughout the world because of the 
increasing death rate due to them. CLDs such as alcoholic liver disease (ALD), nonalcoholic 
fatty liver disease (NAFLD), and viral hepatitis (B and C) progress to fibrosis, cirrhosis, and 
ultimately hepatocellular carcinoma (HCC) [12, 13]. HCC is the fifth most common type of 
cancer and third most common cause of cancer mortality throughout the world [14]. Globally, 
liver cancer is responsible for causing more than 700,000 deaths annually [15]. Oxidative stress 
resulting from various sources is a major mechanism for hepatic fibrosis and cirrhosis [16]. 
Descriptive Food Science94
The major source of ROS in hepatocytes is the mitochondria. Hepatocytes contain many mito-
chondria and thus have high production of ROS. An imbalance between the production of 
ROS and antioxidant defense generates various pathophysiological alterations in the hepatic 
cells, such as activation of hepatic stellate cells (HSCs), initiation of collagen formation, and 
beginning of proliferative processes [17–21]. HSCs are responsible for storage of more than 
90% of the body’s vitamin A content as retinyl esters in normal liver. Chronic liver injuries 
may cause these cells to undergo activation and lose their capacity to store vitamin A while 
acquiring pro-inflammatory and proliferative properties, responsible for fibrogenesis [22]. 
Fibrosis if not treated may lead to end stage of liver damage, that is, liver cancer (Figure 1) 
[15, 23, 24].
In this context, dietary carotenoids being an important part of antioxidant defense system 
and precursor of vitamin A play an important role in the prevention of chronic liver diseases. 
Nowadays, due emphasis is given on the search of alternative therapeutics or medicines as 
these have least side effects and are cost effective. In this context, this chapter focuses on the 
use of dietary carotenoids in chronic liver disease prevention which have been documented 
extensively in the recent literature.
2. β-Carotene and chronic liver diseases
β-Carotene is the major carotenoid present in human diet. It is mainly present in plant sources 
of human diet such as carrots, pumpkin, spinach, sweet potato, cantaloupe, papaya, and man-
goes [25]. It is a potent quencher of singlet oxygen, scavenges peroxy radicals, reduces levels of 
reactive oxygen species, and augments the investigated antioxidant enzyme activities [26, 27]. 
It is also a precursor of vitamin A and is reportedly converted to vitamin A by the action of 
β-carotene 15,15′-monooxygenase [10].
Various studies have demonstrated the hepatoprotective potential of β-carotene carried out 
in animal models, cell lines, and human beings. Patel and Sail reported that β-carotene pro-
tects the physiological antioxidants against aflatoxin-B1-induced carcinogenesis in albino 
rats [28]. β-Carotene supplementation increases the levels of vitamin C, glutathione, and 
glutathione-related enzymes which function as free radical scavenger and, thus, reduces the 
toxicity of aflatoxin-B1 in rats. In another study, it was found that various antioxidants includ-
ing β-carotene modulate the hepatotoxicity induced by aflatoxin-B1 [29]. Both HBV and HCV 
have been found to elevate inflammatory and oxidative conditions in hepatocytes. Moreover, 
in chronic liver diseases, hepatic stellate cells, which store almost 70–90% of vitamin A, become 
activated, lose their retinoid content, and produce extracellular matrix, which is responsible 
for liver fibrosis [30]. Hepatic fibrosis can lead to cirrhosis and in some cases hepatocellular 
carcinoma (HCC). Through its provitamin A activity and roles in inhibiting reactive oxygen 
species, β-carotene has been shown to ameliorate the development and progression of HBV- 
and HCV-induced HCC. In a human study, it was found that the oxidative stress increased 
in patients with chronic hepatitis C (CHC). Various antioxidants such as retinol, α- and 
γ-tocopherol, β-cryptoxanthin, lycopene, and α- and β-carotene were decreased in serum of 
CHC patients, and levels in liver tissue seem to reflect serum levels [31]. In Chinese patients, 
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it was observed in Chinese patients that the serum levels of retinoids are low in HBV-induced 
HCC [32, 33]. In another study, it was shown that a high percentage of patients have vitamin 
A deficiency in serum in chronic hepatitis C [34, 35]. This condition reflects no response to 
antiviral therapy, indicating that serum levels of vitamin A could regulate the responsiveness 
to interferon-based antiviral therapy [35].
The generation of very high levels of oxidative stress during the metabolism of alcohol may 
exceed the antioxidant defense ability of the body and cause the development of liver dys-
function. It has been reported that β-carotene exerts protective effect on chronic ethanol-fed 
rats [36]. It was shown that ethanol treatment causes increase in oxidative stress which could 
stimulate apoptosis in the liver, thus leading to liver injury. However, the lower dose of 
β-carotene supplementation (0.52 mg/kg BW/day), which acted as an antioxidant, decreased 
the ROS level by downregulating lipid peroxidation and CYP2E1 expression. Moreover, 
it prevented ethanol-induced liver damage by impeding hepatic apoptosis via inhibiting 
caspase-9 and caspase-3 expressions and increasing Bcl-xL expression in the liver. In addi-
tion, the higher dose of β-carotene supplementation (6.2 mg/kg BW/day) possibly halted 
ethanol-induced liver damage through inhibiting TNF-α secretion and lipid peroxidation 
in ethanol-fed rats. Literature revealed that β-carotene supplementation can prevent liver 
damage in rats with chronic alcohol consumption [37, 38]. β-carotene supplement is known 
to attenuate ethanol-induced liver damage, decreased oxidative stress and increased GSH 
concentrations in erythrocytes and the liver. β-Carotene may act as an antioxidant, scaveng-
ing lipophilic radicals produced by ethanol within the membranes [39]. In a human study, 
it was found that in alcoholic patients with liver damage, the plasma β-carotene level was 
found to be lowered than in control subjects [40]. ALD is also associated with depleted levels 
of hepatic vitamin A [41]. As β-carotene is the precursor of vitamin A, thus, the supple-
mentation of this carotenoid tends to regain the hepatic vitamin A content, thus facilitating 
attenuation of the disease.
In a study, it was found that dietary intake of apricot reduced the risks of hepatic steatosis and 
damage induced by CCl
4
 in Wistar rats [42]. Apricot is believed to have high content of carot-
enoids, especially β-carotene. Markers of oxidative stress such as malondialdehyde, total GSH 
levels, catalase, SOD, and GSH peroxidase activities were significantly altered by CCl
4
 indicat-
ing increased oxidative stress. Hepatic damage and steatosis imposed by high concentration of 
ROS were ameliorated by β-carotene-rich apricot intake. Consumption of tomato juice which 
contains lycopene and β-carotene as the major components reduces plasmatic triglycerides, 
steatosis, and very low-density lipoproteins. Also, it elevates lipid metabolism by inducing 
the overexpression of genes involved in more efficient fatty acid oxidation in rats [43]. It is 
also shown that Campari tomato, which contains more β-carotene and lycopene than regular 
tomato, ameliorated diet-induced obesity, dyslipidemia, and hepatosteatosis via downregu-
lation of gene expression related to lipogenesis in the zebra fish model. It decreased sterol 
regulatory element-binding transcription factor 1 (SREBF1) mRNA by increasing the forkhead 
box O1 (foxo1) gene expression. This may be due to high percentage of β-carotene in this strain 
of tomato which is responsible for downregulating the expression of SREBF1 [44]. In Chinese 
population greater levels of carotenoids such as β-carotene in serum have been correlated 
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with low prevalence of NAFLD [45]. These carotenoids mediate the protective effects against 
NAFLD through antioxidant mechanism, enhancing gap junction communication, reducing 
inflammation, and modulation of gene expression. In another human study, it was found that 
NAFLD has reverse relationship with vitamin A nutritional status in individuals with class 
III obesity. Retinol and β-carotene serum levels were evaluated as biochemical indicators. 
The researchers observed low serum retinol and β-carotene serum levels in the patients with 
NAFLD [46].
In one study, β-carotene and vanadium inhibit the diethylnitrosamine (DEN)-induced 
hepatic carcinogenesis in rats [47]. It was observed that treatment of β-carotene and vana-
dium reduced the number and size of the hyperplastic nodules significantly, while the 
combination treatment proved as an additive effect, decreasing number and size of the 
hyperplastic nodules from 89 to 22%. Further, it significantly reduced the level of cytosolic 
glutathione and glutathione-S-transferase (GST) activity and stabilized the aerobic metabo-
lism and hepatic architecture of the cells. In another study involving cell lines, it was found 
that acyclic retinoid (synthetic analog of retinoids) retards overexpression of Ras/Erk sig-
naling system, thereby declining the progression of HCC [48]. In a human study, it was 
found that greater intake of retinol, total vitamin A, and carotenes decreases the risk of 
primary liver cancer at an intake of 1000 μg retinol equivalent (RE)/day or greater from food 
sources [49]. In another human study in the presence of hepatitis B virus, levels of dietary 
and serum vitamin A and β-carotene were significantly lower in HCC patients than in the 
control subjects [32].
3. Lycopene and chronic liver diseases
Lycopene, like other carotenoids, is a natural pigment mainly present in tomato and products 
of tomato. It is also present in watermelon, apricot, pink guava, pink grapefruit, and papaya 
[50]. It does not show provitamin A activity since it lacks the β-ionone ring structure which 
is characteristic in other carotenes that are precursors of vitamin A [50, 51]. Various studies 
showed that lycopene possesses antioxidant, anticancer, anti-cardiovascular disease, and 
detoxification abilities in many epidemiological and animal experiments with few side effects 
[52, 53, 54].
As a dietary phytochemicals, lycopene has been demonstrated to mitigate AFB1-induced 
adverse effects in vitro and in vivo. The carcinogenicity of aflatoxin B1 (AFB1) in HepG2 
cells was prevented by lycopene through decreasing DNA damage and AFB1-N7-guanine 
(AFB1-N7-Gua) adduct formation [55]. In another study, it was found that lycopene, because 
of its high antioxidant activity and free radical scavenging capacity, has been shown to 
be effective against oxidative stress due to aflatoxin. Lycopene blocks phase 1 metabolic 
enzymes of AFB such as 3A4, 2A6, and 1A2 [56]. In another study, lycopene relieves AFB1-
induced liver injury through enhancing hepatic antioxidation and detoxification potential 
with Nrf2 activation [57]. Lycopene, a nutritional antioxidant, has also been shown for its 
hepatoprotective potential in D-galactosamine/lipopolysaccharide (D-GalN/LPS)-induced 
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hepatitis in rats [58, 59]. It is able to affect the lipoprotein metabolism by restoring the 
altered levels of lipid-metabolizing enzymes and stabilizing the arrangement of lipoprotein 
levels during experimentally induced hepatitis. Another study demonstrated that the regu-
lar use of our carotenoid-based functional food minimizes the severity of ribavirin-induced 
anemia in patients with CHC and improves tolerance to the full dose of antiviral therapy 
[60]. It was found that a mixture of various carotenoids particularly lycopene seems to be 
promising for the prevention of liver cancer in hepatitis virus-infected patients with cir-
rhosis [61, 62].
It is found that tomato powder which is rich in lycopene acts as a novel candidate for pre-
vention against alcohol-related hepatic injury in rodents [63]. It provides protection against 
alcohol-induced liver injury by suppressing CYP450 2E1 induction. It has been reported that 
lycopene prevents nonalcoholic steatohepatitis induced by high-fat diet [64, 65, 66]. It can 
reduce high-fat diet-induced steatohepatitis by reducing oxidative stress to the cells. It has 
been also shown that incorporation of lycopene in balanced diet prevents NAFLD [67, 68]. 
Lycopene may be a useful functional compound for treating NAFLD by regulating hepatic 
lipid metabolism [69]. Lycopene inhibits the downregulation of miR-21, which led to the 
downregulation of fatty acid-binding protein 7 (FABP7) at both the transcriptional and trans-
lational levels, thus inhibiting hepatic steatosis induced by high-fat diet.
Lycopene also showed beneficial effects against hepatocellular carcinoma. It provides pro-
tection against HCC by modulation of cellular proliferation, glycolysis, and ultrastructure 
of hepatic cells [70]. Lycopene supplementation also prevents high-fat diet-induced HCC 
incidence in mice. It suppressed oncogenic signals, including methionine mRNA, β-catenin 
protein, and mammalian target of rapamycin (mTOR) complex 1 activation. These results 
provide novel experimental evidence that dietary lycopene and its metabolites can be used to 
prevent liver cancer and reduce cancer risk in patients with NAFLD [71].
4. Lutein and chronic liver diseases
Lutein is a non-provitamin A carotenoid that belongs to the oxycarotenoid family. It is present 
in dark green leafy vegetables, such as kale and spinach and eggs [72, 73]. It is commercially 
prepared from the marigold flower (Tagetes erecta L.) in which it occurs at 1.5–1.8%. It directly 
quenches free radicals, especially singlet oxygen species [74].
Lutein possesses an antiviral activity against hepatitis B. It exerts its antivirus effects through 
inhibition of hepatitis B virus transcription [75]. Because of its strong antioxidant potential, 
lutein has been shown to provide protection against ethanol-induced hepatic damage [76]. 
It increases levels of antioxidant enzymes, like superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione, and decreases levels of hydroxyproline. Another study demon-
strated that lutein attenuates alcohol-induced liver damage in rats by regulating inflamma-
tion and oxidative stress [77]. Its supplementation downregulated inflammatory proteins and 
cytokines with collateral upregulation of Nrf2 levels and antioxidant enzymatic activities. 
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Lutein decreases inflammation and oxidative stress in the liver and eyes of guinea pigs fed 
with hypercholesterolemic diet [78]. This carotenoid could prevent degenerative conditions 
of the liver by decreasing the free cholesterol pool and attenuating lipid peroxidation and pro-
inflammatory cytokine production. Further, attenuated inflammatory state in the liver could 
be explained by decreased NF-κB DNA-binding activity. Another study demonstrated that 
lutein possesses ameliorative effect against NAFLD [79]. It suggests that lutein supplementa-
tion could protect against hepatic lipid accumulation and insulin resistance induced by high-
fat diet, possibly via the activation of the expression of sirtuin 1 (SIRT1) and, subsequently, 
peroxisome proliferator activated receptor (PPAR)-α and other key factors in insulin signaling 
[80]. Sirtuin 1 is reported to have therapeutic potential in NAFLD and play a key role in 
insulin sensitivity. SIRT1 regulates the expression of PPAR-α, a key factor in the regulation 
of lipid metabolism [81, 82]. Lutein has also been found to have anticarcinogenetic effects 
against NDEA-induced HCC in rats [83]. Inhibition of carcinogenesis by this carotenoid could 
be because of the combined effect of its antioxidant activity along with the inhibition of cyto-
chrome P450 enzymes, inducing detoxifying enzymes such as glutathione-S-transferase and 
UDP glucuronyl transferase.
5. β-Cryptoxanthin and chronic liver diseases
β-Cryptoxanthin is an oxygenated carotenoid usually present in squash, pepper, papaya, 
sweet pickles, carrots, and orange juice [84]. It is a xanthophyll carotenoid specifically found 
in the Satsuma mandarin (Citrus unshiu Marc.). Similar to other carotenoids, β-cryptoxanthin 
has an antioxidant activity [85, 86]. β-Cryptoxanthin is readily absorbed and relatively abun-
dant in human plasma, together with β-carotene, lycopene, lutein, and zeaxanthin [87].
It has been shown that β-cryptoxanthin ameliorates diet-induced nonalcoholic steatohepatitis 
by repressing inflammatory gene expression in mice [88]. β-Cryptoxanthin suppressed the 
expression of lipopolysaccharide (LPS)-inducible and TNFα-inducible genes in NASH. Elevated 
levels of the oxidative stress marker thiobarbituric acid-reactive substances (TBARS) were 
lowered by β-cryptoxanthin in NASH. Thus, it represses inflammation and the resulting fibro-
sis probably by primarily repressing the increase and activation of macrophages and other 
immune cells. Reducing reactive oxygen species is likely to be a major mechanism of inflam-
mation and injury suppression in the livers of mice with NASH. Another study revealed 
that β-cryptoxanthin reversed steatosis, inflammation, and fibrosis progression in preexist-
ing NASH in mice [89]. Thus, β-cryptoxanthin prevents and reverses insulin resistance and 
steatohepatitis through decreasing activation of macrophages or Kupffer cells in a lipotoxic 
model of NASH. It was found that plasma levels of carotenoids such as β-carotene, lycopene, 
lutein, and β-cryptoxanthin were decreased in patients with NASH [90]. This study suggests 
that antioxidant supplementation may be a rational option for the treatment of NASH. In 
patients of NAFLD, it was found that β-cryptoxanthin treatment inhibits its progression [91]. 
β-Cryptoxanthin supplementation is very effective in raising antioxidant and anti-inflamma-
tion activities in patients of NAFLD (Table 1).
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S. No. Carotenoid investigated Object of study Results References
1 β-Carotene Rat liver Liver antioxidant enzymes such as 
glutathione peroxidase, glutathione-
S-transferase, catalase, and vitamin C 
were elevated
[28]
2 β-Carotene, vitamin E, 
selenium, silymarin, and 
coenzyme Q
10
Rat liver β-Carotene intake restored the levels 
of hepatic glutathione, RNA, and 
serum protein thiols relative to control 
animals
[29]
3 β-Carotene Rat liver Oxidative stress is decreased by 
CYP2E1 expression and lipid 
peroxidation. β-Carotene also inhibited 
hepatic apoptosis via inhibiting 
caspase-3 and caspase-9 and increasing 
Bcl-xL expression in the liver
[36]
4 Retinol, α- and 
γ-tocopherol, lutein, 
β-cryptoxanthin, lycopene, 
and α- and β-carotene
Human liver and 
serum
Increased oxidative stress is present 
in patients with chronic hepatitis 
C. Antioxidants were severely depleted 
in serum and liver tissue
[31]
5 β-Carotene Rat liver β-Carotene prevented ethanol-induced 
lipid peroxidation in hepatic tissues
[38]
6 β-Carotene Rat liver Malondialdehyde, total glutathione 
levels and catalase, superoxide 
dismutase, and glutathione peroxidase 
activities were restored
[42]
7 α- and β-Carotene, lutein, 
and zeaxanthin
Human serum Serum carotenoid levels were inversely 
associated with the risk of NAFLD
[45]
8 Dietary carotenes and 
vitamin A
Human liver Dietary consumption of retinol, 
carotenes, and total vitamin A 
decreases the risk of primary liver 
cancer risk
[49]
9 β-Carotene, β-apo-8′-
carotenal, canthaxanthin, 
astaxanthin, and lycopene
Rat liver Carotenoids exert protective effect 
against aflatoxin B1-induced liver 
preneoplastic foci and DNA damage
[55]
10 Lycopene Rat liver Enhanced hepatic antioxidant and 
detoxification potential
[57]
11 Lycopene Rat liver Liver function test enzymes, 
cholesterol, triglycerides, free fatty 
acids, and phospholipids in serum and 
liver were restored
[58]
12 Lycopene Rat liver It restored the increase in very-low-
density lipoproteins, decrease in 
high-density lipoproteins, and lipid-
metabolizing enzymes
[59]
13 Lycopene Rat and mouse liver Hepatic CYP2E1 protein levels, 
peroxisome proliferator-activated 
receptor-α, inflammatory gene 
expression, and reticulum stress 
markers were restored
[63]
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14 Lycopene Rat liver Supplementation with lycopene 
lowered serum malondialdehyde and 
tumor necrosis factor (TNF-α) levels 
and elevated liver GSH level
[64]
15 Lycopene Rat liver Lycopene treatment reverted changes 
in liver weight, serum low-density 
lipoproteins, total hepatic cholesterol, 
and activity of hepatic SOD, catalase, 
and glutathione peroxidase
[68]
16 Lycopene Rat liver Lycopene supplementation 
downregulated TNF-α and CYP2E1 
expression and decreased infiltration 
of liver fats
[67]
17 Lycopene Rat liver Lycopene provides protection against 
NAFLD by alleviating amino acid 
depletion, recovery of the redox 
balance in liver, and incrementing 
L-carnitine levels
[65]
18 Lycopene Mouse liver It decreases the expression of cell 
proliferation-associated genes (PCNA, 
cyclin D1, and p21) and glycolytic 
enzymes
[70]
19 Lycopene Mouse liver Lycopene and its metabolites reduce 
cancer in NAFLD
[71]
20 Lutein Human 
hepatoblastoma cells
Lutein inhibited the activity of HBV 
full-length promoter
[75]
21 Lutein Rat liver SOD, catalase, glutathione peroxidase, 
glutathione, and hepatic hydroxyproline 
content were restored by lutein
[76]
22 Lutein Rat liver Inflammatory proteins such as NF-κB, 
COX-2, and iNOS were downregulated 
along with the upregulation of Nrf2 
levels and activities of antioxidant 
enzymes
[77]
23 Lutein Rat liver Lutein administration decreased 
serum and hepatic cholesterol and 
triglyceride. It also increased the 
expression of key factors involved in 
hepatic insulin signaling
[79]
24 Lutein Rat liver Lutein treatment inhibits cytochrome 
P450 enzymes and increases 
detoxifying enzymes such as 
glutathione-S-transferase and UDP 
glucuronyl transferase
[83]
25 β-Cryptoxanthin Mouse liver β-Cryptoxanthin reduced the levels of 
TBARS and suppressed the expression 
of lipopolysaccharide and TNF-α 
inducible gene. It further suppressed 
the activation of macrophages, T 
helper, and cytotoxic cells
[88]
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6. Other carotenoids and chronic liver diseases
Other carotenoids such as α-carotene, fucoxanthin, and zeaxanthin also show promising 
effects against chronic liver injury. It has been found that α-carotene has an inhibitory effect 
on spontaneous liver carcinogenesis in male mice [92]. α-Carotene significantly decreases the 
mean number of hepatomas per mouse. In another study, it was found that fucoxanthin pro-
moted weight loss, reduced body and liver fat content, and improved liver function tests in 
obese nondiabetic women [93]. Zeaxanthin also shows protective effects against nonalcoholic 
steatohepatitis [94]. It significantly prevented NASH progression by decreasing oxidative 
stress and liver fibrosis. It has been found also that zeaxanthin showed therapeutic effects 
against alcoholic liver diseases [95]. Zeaxanthin show protective effects through the lower 
expression level of cytochrome P450 2E1 (CYP2E1), diminished activity of nuclear factor 
kappa B (NF-κB) through the restoration of its inhibitor kappa B alpha (IκBα), and the modu-
lation of MAPK pathways including p38 MAPK, JNK, and ERK.
7. Conclusions and future directions
Various epidemiological studies investigate the effects of dietary carotenoids on various 
markers of oxidative stress and inflammation indicating their preventive role in chronic liver 
disease prevention. Oxidative stress is clearly associated with the etiology of chronic liver 
diseases. Thus, the use of carotenoid-rich fruits and vegetables should be the part of diet  
(Tables 2 and 3). Although several pathways related to inhibition of oxidative stress by carot-
enoids have been uncovered, many aspects remain poorly understood and warrant further 
research. As many carotenoids have been found to have provitamin A activity, the mecha-
nism related to their regaining of vitamin A content by hepatic stellate cells and restoring their 
normal functions should be properly understood (Figure 2).
There is further need of long-term controlled trials in normal and diseased groups to study the 
dose response of each dietary carotenoid. Future research areas may include their bioavail-
ability, metabolism, safety, and mechanism of action. Studies on the type of carotenoid and 
its metabolites which may act as a suitable regulator to alter pathways related to oxidative 
S. No. Carotenoid investigated Object of study Results References
26 β-Cryptoxanthin Mouse liver β-Cryptoxanthin reduced total hepatic 
macrophage content
[89]
27 β-Cryptoxanthin Human liver β-Cryptoxanthin induced antioxidant 
and anti-inflammatory activities in 
NAFLD patients
[91]
28 Fucoxanthin Human liver It reduced liver and body fat content 
and improved liver function tests
[93]
Table 1. Effects of carotenoids on chronic liver diseases in cell line, human, and animal models.
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stress, inflammation, and carcinogenicity shall also be among the priority areas. However, 
studying the molecular targets of these dietary carotenoids cannot be ignored and be given 
full consideration.
Dietary sources β-Carotene Lycopene Lutein β-Cryptoxanthin
Apricot (dried) 17.6$ 0.9$ — —
Carrot (raw) 7.9$ — — —
Spinach (raw) 4.1$ — 11.9$ —
Kale 4.7$ — 15.8$ —
Tomato juice — 8.6$ — —
Avocado (raw) 0.053# — — 0.036#
Grape fruit, pink (raw) — 3.4$ — —
Guava (raw) — 5.4$ — —
Corn, sweet (cooked) — — 1.8$ —
Papaya (raw) 0.276# — — 0.761#
Orange (raw) 0.051# — 0.187# 0.122#
Sweet potato (raw) 8.8$ — — —
Lettuce (raw) 1.27# — 2.6# —
Watermelon (raw) 0.295# 4.8# 0.017# 0.105#
Cabbage (raw) 0.065# — 0.310# —
Broccoli (raw) 2.4# — 0.78# —
Brussels sprouts (raw) 0.45# — 1.5# —
Peas, green (raw) 0.48# — — —
Tangerine (raw) 0.071# — 0.243# 0.485#
Pepper, sweet red (raw) 2.379# — — 2.205#
#Derived from Arscott [96].
$Derived from Johnson [97].
Table 2. Dietary sources of major carotenoids (mg/100 g).
S. no. Carotenoid Recommended daily dose (mg) References
1 β-Carotene 7 [98]
2 Lycopene 35 [99]
3 Lutein 1–4 [100]
4 β-Cryptoxanthin 3 [91]
Table 3. Ingestion levels of dietary carotenoids to prevent liver diseases.
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Figure 2. Hypothesis of progression of chronic liver diseases and their prevention by dietary carotenoids.
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